NORLESTRIN 21 1/50 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Norlestrin 21 1/50, and when can generic versions of Norlestrin 21 1/50 launch?
Norlestrin 21 1/50 is a drug marketed by Parke Davis and is included in one NDA.
The generic ingredient in NORLESTRIN 21 1/50 is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for NORLESTRIN 21 1/50?
- What are the global sales for NORLESTRIN 21 1/50?
- What is Average Wholesale Price for NORLESTRIN 21 1/50?
Summary for NORLESTRIN 21 1/50
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 5 |
| Patent Applications: | 130 |
| DailyMed Link: | NORLESTRIN 21 1/50 at DailyMed |
US Patents and Regulatory Information for NORLESTRIN 21 1/50
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parke Davis | NORLESTRIN 21 1/50 | ethinyl estradiol; norethindrone acetate | TABLET;ORAL-21 | 016749-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
